ACE2 News and Research

RSS

Patients treated with ACEIs and ARBs may be at increased risk of severe COVID-19

James Diaz, MD, MHA, MPH & TM, Dr PH, Professor and Head of Environmental Health Sciences at LSU Health New Orleans School of Public Health, has proposed a possible explanation for the severe lung complications being seen in some people diagnosed with COVID-19.

23 Mar 2020

World’s fastest supercomputer identifies chemicals with potential to stop COVID-19

What makes the coronavirus disease (COVID-19) global pandemic different from the Spanish flu in 1918? In 1918, transportation, technology, and science were in their infancy, with the medical field not capable of fighting outbreaks. Technology has come a long way, within days, scientists have already identified the type of virus spreading in China, and three months after, vaccine trials have started.

20 Mar 2020

COVID-19 epidemic is the product of natural evolution, study finds

The novel SARS-CoV-2 coronavirus that emerged in the city of Wuhan, China, last year and has since caused a large scale COVID-19 epidemic and spread to more than 70 other countries is the product of natural evolution, according to findings published today in the journal Nature Medicine.

17 Mar 2020

What does COVID-19 do to the body?

The novel coronavirus SARS-CoV-2, also known as 2019-nCoV, is the virus that causes COVID-19, and that is spreading throughout the world is causing panic in almost all countries. With a death rate ranging from 1% to 2% in young patients but about 5%-8% in elderly and sick patients, it is capable of ravaging multiple organ systems in the human body.

12 Mar 2020

Scientists may have found a way to prevent coronavirus spread

Just like any other virus, the coronavirus needs a host to survive. Viruses enter the cells of the human body to cause disease by attaching to a specific receptor site on the host cell membrane. To do this, they attach to proteins in the capsid through glycoproteins found in the envelope of the virus.

8 Mar 2020

The changing face of the COVID-19 epidemic

The SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) virus, which hit China with the disease now named COVID-19 in December 2019 and has since spread to over 70 countries, has caused over 90,000 cases, and 3,117 fatalities, with 95% or more of both being in China.

2 Mar 2020

APEIRON Biologics launches clinical trial of respiratory drug to treat coronavirus infection

APEIRON Biologics AG, a biotechnology company with an approved product on the market as well as a broad preclinical and clinical pipeline, today announced the launch of a Pilot investigator-initiated clinical trial with APN01, a recombinant human angiotensin-converting enzyme 2, to treat patients with severe coronavirus infection in the People's Republic of China.

26 Feb 2020

Advancing a protein drug in lettuce leaves to treat pulmonary arterial hypertension

In pulmonary arterial hypertension, high blood pressure in the lungs' arteries causes the heart to work extra hard to pump blood to the lungs and around the rest of the body.

16 Feb 2020

Promising new drug may offer effective treatment for heart failure patients

Heart failure patients who are getting by on existing drug therapies can look forward to a far more effective medicine in the next five years or so, thanks to University of Alberta researchers.

8 Mar 2017

Potential new intraocular treatment based on RAS manipulation can prevent or reverse diabetic retinopathy

Pathologic changes of the retina caused by diabetes is the leading cause of blindness in working adults. Diabetic retinopathy has no known cure, treatment options are inadequate, and prevention strategies offer limited protection. In the first of its kind, a report in The American Journal of Pathology describes a potential new intraocular treatment based on manipulating the renin angiotensin system (RAS) that both prevents and reverses some characteristics of diabetic retinopathy in a mouse model.

10 May 2016

EcoHealth Alliance discovers new SARS-like coronavirus in Chinese horseshoe bats

EcoHealth Alliance, a nonprofit organization that focuses on local conservation and global health issues, announced the discovery of a new SARS-like coronavirus (CoV) in Chinese horseshoe bats.

31 Oct 2013

New coronavirus can infect cells from humans and bats alike

The SARS epidemic of 2002-2003 was short-lived, but a novel type of human coronavirus that is alarming public health authorities can infect cells from humans and bats alike, a fact that could make the animals a continuing source of infection, according to a study to be published in in mBio-, the online open-access journal of the American Society for Microbiology, on December 11.

11 Dec 2012

Molecular explanation for increased susceptibility to intestinal inflammation in malnutrition

More than one billion people in poor countries are starving, and malnutrition remains a major problem even in rich countries, making it a leading cause of death in the world. For over a hundred years, doctors have known that a lack of protein in the diet or low levels of amino acids, the building blocks of proteins, can lead to symptoms like diarrhoea, inflamed intestines and other immune system disorders, which weaken the body and can be fatal. However, the molecular mechanism which explains how malnutrition causes such severe symptoms has been largely unexplored.

26 Jul 2012

ACE2 molecule now protects major organs in diabetic patients

ACE2, a molecule that has been shown to prevent damage in the heart, is now proving to be protective of the major organs that are often damaged in diabetic patients.

17 May 2012

Factors of hormone metabolism may make African-Americans more susceptible: Study

High blood pressure also called hypertension is a major health problem that when left untreated can lead to heart disease, stroke and kidney failure. African Americans are more likely to develop high blood pressure and develop it earlier in life than Caucasians. But the reasons for the heightened risk in African Americans still remained largely unknown, although new evidence may provide some insight.

26 Apr 2010

Hundred millions for biotech-licence

Apeiron Biologics AG (Apeiron) today announced the signing of an agreement granting GlaxoSmithKline (GSK) exclusive rights to APN01 (recombinant human Angiotensin Converting Enzyme 2, rhACE2), an enzyme biotherapeutic currently in Phase 1 development for the treatment of the Acute Respiratory Distress Syndrome (ARDS).

3 Feb 2010

Alternative therapy for hypertension

New research from the Northwestern University Feinberg School of Medicine has found that an alternative therapy may be possible for treating some types of hypertension using an enzyme called ACE2.

18 Dec 2009

Ore Pharmaceutical Holdings reports financial results and provides operational updates for third quarter 2009

Ore Pharmaceutical Holdings Inc. today reported financial results and provided an operational update for the third quarter ended September 30, 2009.

13 Nov 2009

Canadian Cardiovascular Society to honor University of Alberta medical researcher

A University of Alberta medical researcher being hailed as a world leader in his field will receive a major national award for his pioneering work in the development of a new class of drugs for the treatment of heart failure.

23 Oct 2009

Regulatory differences between mother and daughter cells shed new light on cell division

When mother and daughter cells are created each time a cell divides, they are not exactly alike. They have the same set of genes, but differ in the way they regulate them. New research now reveals that these regulatory differences between mother and daughter cells are directly linked to how they prepare for their next split.

20 Oct 2009